Physician

Bryan D Gescuk, M.D.

According to 2025 Medicare claims, Bryan Gescuk, M.D. (NPI: 1295815579) practices rheumatology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is SAN MATEO RHEUMATOLOGY INC. (NPI: 1104201334; TIN: 474083009) and primary practice location at 94401-3844.

Gescuk's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 374 traditional Medicare patients, billed 76,278 HCPCS/CPT codes, and received $1,147,150 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,550 prescription claims across 439 beneficiaries totaling $4,325,330 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 346 records totaling $129,815. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $11,013 to $1,147,150. Similarly, Part D prescription costs have moved sharply higher in recent years, from $700,042 to $4,325,330. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	79	205	$11,013
2016	94	284	$13,656
2017	120	749	$30,309
2018	194	12,229	$381,613
2019	218	18,676	$565,719
2020	165	18,688	$427,309
2021	156	20,531	$314,835
2022	195	34,492	$421,451
2023	241	36,953	$500,668
2024	374	76,278	$1,147,150

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	117	1,179	$700,042
2016	130	1,429	$1,220,241
2017	158	1,457	$1,546,690
2018	226	1,700	$1,880,029
2019	252	1,832	$1,931,245
2020	240	1,794	$2,263,814
2021	265	1,816	$2,531,131
2022	284	1,931	$3,013,159
2023	313	1,929	$3,735,055
2024	439	2,550	$4,325,330

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	68	68	$150
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	287	541	$116
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	81	182	$76
J0897	Injection, denosumab, 1 mg	74	6,780	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	170	266	$15

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	132	4,064	$1,046,638
Rinvoq	Upadacitinib	114	4,020	$831,533
Enbrel Sureclick	Etanercept	49	1,932	$505,550
Xeljanz Xr	Tofacitinib Citrate	65	1,950	$370,181
Skyrizi Pen	Risankizumab-Rzaa	11	942	$222,194

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	346	$129,815	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bryan D. Gescuk, M.D.?

Tedicare shows public-source Medicare data for Bryan D. Gescuk, M.D. (NPI 1295815579), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bryan D. Gescuk, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bryan D. Gescuk, M.D.?

Bryan D. Gescuk, M.D. is linked to SAN MATEO RHEUMATOLOGY INC. (billing NPI 1104201334) in the available physician profile data.

Does Bryan D. Gescuk, M.D. have Open Payments data?

Bryan D. Gescuk, M.D. has 346 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.